| Prev Close | 50.51 |
| Open | 49.89 |
| Day Low/High | 49.76 / 50.06 |
| 52 Wk Low/High | 37.62 / 55.00 |
| Volume | 4.49M |
| Avg Volume | 1.74M |
Sanofi (SNY)
49.91
0.60
1.19
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 2.51B |
| Market Cap | 129.93B |
| EPS | 1.30 |
| P/E Ratio | 27.16 |
| Div & Yield | 1.17 (2.28%) |
7 Things to Watch in Biotech Now
M&A, drug approvals and Trump are all on my watch list.
4 Biotech Names That Could Be M&A Targets
Animal health and oncology deal activity is heating up in 2017.
Jim Cramer Sees Buying Opportunities in Praluent Patent Suit
After a court halts Regeneron's sales of Praluent, Jim Cramer sees opportunity in Amgen.
Regeneron Cholesterol-Lowering Drug Banned From U.S. Market
A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.
J&J Is Being Disciplined by Abandoning Merger Talks With Actelion, Jim Cramer Says
Jim Cramer comments on Johnson & Johnson's move to abandon merger talks with Actelion.
Donald Trump Election Victory Boosts Some Stocks and Sectors
As we all know, the stock market and the economy abhor uncertainty.
Closing Bell: Regeneron Slides on FDA Ruling; FBI Reopens Clinton Case
It was a volatile end to the week after federal investigators reopened a case into Hillary Clinton's email server.
My Takeaways and Observations
The Chart of the Day demonstrates the widening schism between the real economy and stock prices. The issuance of negative-yielding European corporate debt by Henkel, Deutsche Bahn and Sanofi are the definition of insanity. Euro bond prices are in t...
Tell Me Something I Don't Know
Regular readers of my diary know that I sometimes post something that replicates the theme of the Tell Me Something I Don't Know segment on MSNBC's Hardball With Chris Matthews. So ... "Tell me something I don't know, Dougie." OK, here goes: Henkel ...
Mylan Still Isn't Cheap
The EpiPen controversy makes this stock a shot in the dark.
Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians
Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.
Cramer: It's a Presidential Campaign, So Let the Corporate Bashing Begin
Clinton goes after the drug companies again -- for starters.
Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back
Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.
Biotechs Rally on Pfizer/Medivation Deal
The market is basically flat across the board to start the new week, but biotechs are strong overall in early going following news that Pfizer plans to buy Medivation for $14 billion. The sector's movers include some biotechs that I hold. For instan...
Pfizer Is Buying Medivation for $14 Billion
Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.
Bret Jensen Reporting for Duty
Good morning, Bret Jensen here! It's good to be standing in for Doug Kass again on the daily diary as we begin a new trading week. Biotech -- my favorite subject -- should be a hot topic today after Pfizer appears to have outbid Sanofi for oncology ...
It's 'All Systems Go' for Biotech
The sector seems to be rebounding after tumbling by more than 40%.
Pokèmon Go Is Just the Tip of the Mobile-Gaming Iceberg
The mobile-gaming market is expected to surpass console games this year, according to Deloitte.
Sanofi's Chart Shows Promise
Our first upside target is the $50 to $52 area and a close below $40 would extend the base.
Investors Scour Big Pharma M&A Scene for Next Big Takeover
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
Morning Movers: BCS, LYG, RBS, GOLD, AU, SNY
U.K. banks continue to get crushed in the wake of last week's Brexit vote as gold, a typical safe-haven investment, surged ahead.
BioMarin Pharmaceuticals Jumps on Takeover Talk
Biotech company BioMarin Pharmacuetical's shares are moving sharply higher on heavy volume in Friday's session.
Biotech M&A Waking Up After Long Nap
The uptick in the small- and mid-cap space bodes well for future capital appreciation.
Biotech Is Showing Some Bargains
It is hard to see much growth in the market overall, until earnings growth returns.
Cramer: Worst May Be Over for Embattled Pharma
The M&A activity is an incredible and a welcome sign.
M&A Could Ignite Next Leg Up for Biotech
Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.
A Good Morning So Far
The market is off to a good start, as the futures had portended earlier. Industrial and construction stocks seem to be doing particularly well. Rail-car maker Greenbrier Cos. (GBX) continues to show strength even after a recent earnings report that ...
Novice Trade: GlaxoSmithKline
Owning GSK May calls may give a nice payout on any good news regarding a Zika virus vaccine.
MannKind Investors Should Have Seen the Writing on the Wall
Shareholders should have been running from the drugmaker long before Tuesday's news that partner Sanofi was leaving first.
2016 Could Be the Year of the Eurozone Stock Markets
The ECB's monetary stimulus is working, and more may be on the way.
